Current thoughts on the role of the androgen receptor and prostate cancer progression.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Advances in Anatomic Pathology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.PAP.0000184179.50672.F7PMID 16210922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations in the Androgen Receptor Gene Are Associated with Progression of Human Prostate Cancer to Androgen Independence I

  2008cited by this paper
• Androgen receptor in prostate cancer.

  2004cited by this paper
• The androgen receptor gene mutations database (ARDB): 2004 update

  2004cited by this paper
• Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells

  2004cited by this paper
• Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer*

  2004cited by this paper
• High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate: Cancer Patients Treated With Radical Prostatectomy

  2004cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Emergence of metastatic hormone‐refractory disease in prostate cancer after anti‐androgen therapy

  2004cited by this paper
• Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.

  2004cited by this paper
• Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer

  2003cited by this paper
• Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.

  2003cited by this paper
• The embedded tumour: host physiology is important for the evaluation of tumour growth

  2003cited by this paper
• Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development

  2003cited by this paper
• Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

  2003cited by this paper
• Androgen receptor gene amplification and protein expression in recurrent prostate cancer.

  2003cited by this paper
• Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

  2003cited by this paper
• Androgen Receptor Mutations in High-Grade Prostate Cancer before Hormonal Therapy

  2003cited by this paper
• Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer

  2003cited by this paper
• 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor

  2003cited by this paper
• Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer

  2002cited by this paper
• Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer

  2002cited by this paper
• Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region*

  2001cited by this paper
• The development of androgen-independent prostate cancer

  2001cited by this paper
• Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.

  2001cited by this paper
• Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1

  2001influential reference
• Androgen Receptor Alterations in Prostate Cancer Relapsed during a Combined Androgen Blockade by Orchiectomy and Bicalutamide

  2001cited by this paper
• Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.

  2001cited by this paper
• Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer*

  2001cited by this paper
• Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

  2001cited by this paper
• A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

  2001cited by this paper
• Androgen receptor mutations in prostate cancer.

  2000cited by this paper
• Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

  2000cited by this paper
• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

  1999cited by this paper
• Androgen receptor gene amplification increases tissue PSA protein expression in hormone‐refractory prostate carcinoma

  1999cited by this paper
• Early castration‐induced upregulation of transforming growth factor β1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate‐specific antigen in prostate cancer patients

  1999cited by this paper
• Androgen receptor gene mutations in hormone‐refractory prostate cancer

  1999cited by this paper
• From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

  1999cited by this paper
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

  1999influential reference
• The biology of hormone refractory prostate cancer. Why does it develop?

  1999cited by this paper
• Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer.

  1998cited by this paper
• Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

  1998cited by this paper
• Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification

  1997cited by this paper
• Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

  1997cited by this paper
• Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.

  1996cited by this paper
• Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway*

  1996cited by this paper
• The androgen receptor in prostate cancer.

  1996cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper
• Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

  1995cited by this paper
• Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

  1994cited by this paper
• Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

  1994cited by this paper
• Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

  1993cited by this paper
• Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells.

  1990cited by this paper
• Effect of Transforming Growth Factor-β1 on Proliferation and Death of Rat Prostatic Cells*

  1990cited by this paper
• A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

  1990cited by this paper
• STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND

  1941cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Exploring the Functional Role of Programmed Death‐Ligand 1 (PD‐L1) in the Castration‐Resistant Prostate Cancer Using Transcriptomic Sequencing Analysis

  2025cites this paper
• Molecular Docking Study of Mangosteen (Garcinia mangostana L.) Xanthone-Derived Isolates as Anti Androgen

  2021cites this paper
• Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals conservation of bone microenvironment signatures

  2020cites this paper
• The prostate cancer stem cell niche: Genetic drivers and therapeutic approaches

  2020cites this paper
• Over-Expression of Aryl Hydrocarbon Receptor (AhR) Enhances Src Kinase Activity to Functionally Induce AR Signaling and Promote Prostate Cancer Progression

  2018cites this paper
• Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer

  2018cites this paper
• Androgen receptor: structure, role in prostate cancer and drug discovery

  2014cites this paper
• The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy

  2014cites this paper
• Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancer

  2012cites this paper
• Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist*

  2012cites this paper
• Environmental endocrine disruptors: does a sex-related susceptibility exist?

  2011cites this paper
• Nutrition and human health from a sex-gender perspective.

  2011cites this paper
• Androgen Receptor in Laryngeal Carcinoma: Could There Be an Androgen-Refractory Tumor?

  2011influential citation
• Chemical Biology Screen for Prostate Cancer Therapeutics

  2011cites this paper
• Mechanisms of prostate cancer initiation and progression.

  2010cites this paper
• Androgen receptor modulation by non-androgenic factors and the basal transcription factor TAF1

  2010influential citation
• STEAP1 expression in prostate cancer and its regulation by androgens

  2010cites this paper
• β-TrCP Inhibition Reduces Prostate Cancer Cell Growth via Upregulation of the Aryl Hydrocarbon Receptor

  2010cites this paper
• PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

  2009cites this paper
• Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

  2009cites this paper
• Androgen Controlled Regulatory Systems in Prostate Cancer -Potential new therapeutic targets and prognostic markers

  2008cites this paper
• Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells.

  2008influential citation
• Development of androgen receptor messenger RNA targeted molecular beacons for use in the study of prostate cancer progression

  2008cites this paper
• Growth Hormone Inhibitors in Prostate Cancer: A Systematic Analysis

  2008cites this paper
• Rapid,Non-Destructive,Cell-Based Screening Assays forAgentsThatModulateGrowth,Death, andAndrogenReceptorActivation in ProstateCancerCells

  2007cites this paper
• Rapid, non‐destructive, cell‐based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells

  2007cites this paper
• Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process

  2007cites this paper